Home
News
In Focus
Business
Metro
Nation
World
Sports
Feature
Opinion
View more »Opinion Columns
Wan LixinOpinion deputy editor of Shanghai Daily
Restaurants get off to a quick start thanks to game-changing policies
High service charges on event ticket refunds call for further regulation
Sunday
- Subscribe
Related News
New device helpful in preventing strokes
Source: Agencies |
March 29, 2009, Sunday
|
Print Edition
Print Edition
A new device implanted in the heart proved to be a potential alternative to a standard blood thinner for helping patients with irregular heart beats prevent stroke, researchers who conducted the large American clinical study said yesterday.
The cage-like device reduced the risk of stroke and cardiovascular death by 32 percent compared to warfarin, a widely used blood thinner that is notoriously difficult to manage and carries a high bleeding risk.
The Watchman device, made by Atritech Inc, had twice as many procedure-related complications ?? most of them related to its implantation ?? but researchers concluded it is an effective alternative to warfarin.
"Although there are complications associated with implantation of the device, patients can avoid the need for chronic warfarin therapy, with all its attendant risks," said Dr David Holmes, professor of medicine at the Mayo Graduate School of Medicine in Minnesota, who presented the study at the American College of Cardiology scientific meeting in Orlando.
Atrial fibrillation is a common heart rhythm disorder that creates blood clots and increases the risk of stroke. The disorder is found in about 2.2 million Americans and about 15 percent of strokes occur in people with atrial fibrillation, according to the American Heart Association.
The Watchman is an expandable cage designed to keep harmful blood clots that form in the left atrial appendage of the heart from entering the blood stream and causing a stroke.
The device is guided to the heart through a catheter inserted through a vein in the upper leg.
It is placed just behind or at the opening of the left atrial appendage, where the vast majority of clots are formed, according to Atritech.
In the 707-patient study, 463 atrial fibrillation patients were randomly assigned to the Watchman and 244 patients to warfarin.
The combined rate of stroke and cardiovascular death ?? the primary effectiveness measure ?? was 3.4 per 100 patient years in the device group, compared to five per 100 patient years in the warfarin group.
The cage-like device reduced the risk of stroke and cardiovascular death by 32 percent compared to warfarin, a widely used blood thinner that is notoriously difficult to manage and carries a high bleeding risk.
The Watchman device, made by Atritech Inc, had twice as many procedure-related complications ?? most of them related to its implantation ?? but researchers concluded it is an effective alternative to warfarin.
"Although there are complications associated with implantation of the device, patients can avoid the need for chronic warfarin therapy, with all its attendant risks," said Dr David Holmes, professor of medicine at the Mayo Graduate School of Medicine in Minnesota, who presented the study at the American College of Cardiology scientific meeting in Orlando.
Atrial fibrillation is a common heart rhythm disorder that creates blood clots and increases the risk of stroke. The disorder is found in about 2.2 million Americans and about 15 percent of strokes occur in people with atrial fibrillation, according to the American Heart Association.
The Watchman is an expandable cage designed to keep harmful blood clots that form in the left atrial appendage of the heart from entering the blood stream and causing a stroke.
The device is guided to the heart through a catheter inserted through a vein in the upper leg.
It is placed just behind or at the opening of the left atrial appendage, where the vast majority of clots are formed, according to Atritech.
In the 707-patient study, 463 atrial fibrillation patients were randomly assigned to the Watchman and 244 patients to warfarin.
The combined rate of stroke and cardiovascular death ?? the primary effectiveness measure ?? was 3.4 per 100 patient years in the device group, compared to five per 100 patient years in the warfarin group.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
